In my recent article, I discussed Tekmira Pharmaceuticals (TKMR), a biopharmaceutical company focused on RNAi therapeutics. In this article, I will discuss another small cap biotech company Arrowhead Research Corp (ARWR) which is focused on both RNAi therapeutic and small molecule delivery.
Three Platform Technologies Provide Multiple Applications of Targeted Therapy
Arrowhead Research Corporation is a clinical stage biotech company focused on oncology, obesity, and infectious disease.
Over the years, Arrowhead has developed three proprietary drug delivery platform technologies: Homing Peptides™, Dynamic Polyconjugates (DPCs) ™, and RONDEL™. All three technologies are actively targeted delivery vehicles that can deliver small molecule and siRNA (small interfering RNA) drugs into tissues and cell types of...
Only subscribers can access this article, which is part of the PRO research library covering 3,627 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: